Novo updates 2017 guidance, launches Xultophy

On Wednesday, Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) narrowed its full-year guidance in its 1Q17 earnings report and said it had launched combination therapy Xultophy insulin degludec/liraglutide to treat Type II diabetes.

The news lifted Novo shares by DKK17.90 to DKK282.60 in Copenhagen, and $2.19 to $41.12 in New York...